Australian and New Zealand
Journal of Psychiatry

informa
healthcare

**What are specialist mental health clinician attitudes to
guideline recommendations for the treatment of depression
in young people?**

Journal:	<i>Australian and New Zealand Journal of Psychiatry</i>
Manuscript ID:	ANP-2011-00145.R2
Manuscript Type:	Regular Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Hetrick, Sarah; The University of Melbourne, Orygen Youth Health Research Centre, Centre for Youth Mental Health Simmons, Magenta; The University of Melbourne, Orygen Youth Health Research Centre, Centre for Youth Mental Health Thompson, Andrew; The University of Melbourne, Orygen Youth Health Research Centre, Centre for Youth Mental Health; Orygen Youth Health Parker, Alexandra; University of Melbourne, Orygen Youth Health Research Centre, Department of Psychiatry
Keywords:	depressive disorder, evidence-based practice, mental health services, adolescent, young adult

SCHOLARONE™
Manuscripts

What are specialist mental health clinician attitudes to guideline recommendations for the treatment of depression in young people?

Sarah E Hetrick^{1,3}, Senior Research Fellow
Magenta Simmons¹, Research Fellow
Andrew Thompson^{1,2}, Consultant Psychiatrist
Alexandra G Parker^{1,3}, Senior Research Fellow

- 1. Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Rd, Parkville, VIC, 3052, Australia
- 2. Orygen Youth Health, 35 Poplar Rd, Parkville, VIC, 3052, Australia
- 3. headspace, The National Youth Mental Health Foundation, Centre of Excellence, 47-51 Chetwynd St, North Melbourne, VIC, 3051, Australia

For submission to: Australian and New Zealand Journal of Psychiatry

Date: Second revision submitted 01.08.11

Corresponding author: Dr Sarah Hetrick
Orygen Youth Health Research Centre
Centre for Youth Mental Health
University of Melbourne
35 Poplar Rd, Parkville,
VIC, 3052
Australia
Tel: +61 3 9342 2800
Fax: +61 3 83872466
e-mail: shetrick@unimelb.edu.au

Running head: Clinician attitudes to depression guidelines

Word count: 5572

Abstract*Objectives*

We sought to examine potential barriers to the use of evidence-based guidelines for youth depression in a tertiary specialist mental health service, as part of an initiative to implement evidence based practice within the service.

Methods

This was a qualitative study adopting a social constructionist perspective using focus groups. The focus groups, conducted with all clinicians (medical and allied health), were audiotaped, transcribed and thematic analysis was undertaken. Clinicians were asked about the barriers to implementing four key recommendations from the National Institute for Health and Clinical Excellence (NICE) guidelines.

Results

Barriers existed at 1. the individual clinician level; 2. the clinical level in terms of the presentation of young people; and 3. the service level. The key individual clinician level barrier was a stated belief that the guidelines were not relevant to the young people presenting to the service, with little evidence to guide practice. Related, the main barrier with regard to the clinical presentation was the severity and complexity of this presentation, often making the delivery of interventions like cognitive behavioural therapy (CBT) difficult to deliver. At the service level, a lack of integration with primary and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

secondary level care meant sequencing interventions according to guideline recommendations was difficult.

Conclusions

There is a clear imperative to develop the evidence base to ensure that effective treatments for young people aged up to 25 years with severe and complex disorders that include comorbid conditions, suicide risk and psychosocial difficulties, are investigated and disseminated. Furthermore, this work has highlighted the need for greater investment in models of care that ensure integration between existing primary and secondary care and enhanced specialist early intervention mental health services for young people.

Key words: depressive disorder; evidence-based practice; mental health services; adolescent; young adult

Introduction

There is a high prevalence of depressive disorders in children and adolescents up to 18 years of age (e.g. 1, 2) and these disorders have a significant negative impact on social and occupational functioning (2, 3). Of particular concern is the link between depression and completed suicide in young people (4-8). In the last few years, research has indicated that not only are those with untreated depression at risk of suicide, but that young people up to the age of 25 who are treated with antidepressant medication are more likely to experience an increase in suicidal ideation and suicide attempts (9-11).

This research has led to controversy about what constitutes optimal treatment for depressive disorders, particularly with regard to the role of medication (12-15). There is a relative paucity of large, representative and well-conducted trials in young people (12, 16, 17), particularly those that include participants with severe, complex disorders and suicide risk. In this context, guideline recommendations that aid clinicians to make evidence based treatment decisions that maximize the chance of recovery and minimize the risk of suicidal behaviour, are essential. A number of guidelines for the treatment of depression in young people exist (18-21), most recently an Australian Guideline (22). Key recommendations are relatively consistent across these guidelines, encouraging practitioners to engage in a model of care that sequences interventions from those that are low intensity for mild presentations to more intensive psychotherapy and medication

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(fluoxetine first line) interventions for more severe presentations, and to ensure close monitoring of emergent suicidality.

However, despite the existence and dissemination of guidelines, it is widely recognised that the incorporation of evidence-based recommendations into every day clinical practice is far from universal among clinicians (23). For example, a study of antidepressant use in young people in Australia between 2003 and 2005 showed sertraline was more commonly used (24); American research indicates that monitoring of symptoms and adverse events after prescription of an antidepressant is vastly below what is recommended (25); and UK research shows less than 100% compliance with guideline recommendations (26). The uptake of evidence into everyday clinical practice is best supported by interventions that are specific to the setting, and tailored to address specific barriers to the use of guidelines both at an individual, local and systemic level (23, 27-29). While there are some examples of this approach in mental health (e.g. 30), little has been done in the area of youth depression. Therefore, we sought to examine potential barriers to the use of evidence-based guidelines for youth depression in a tertiary specialist mental health service.

Materials and Methods

Study design

This was a qualitative study using a social constructionist perspective (that assumes individuals and groups participate in the construction of their perceived reality in an ongoing dynamic process) (31, 32), to undertake focus groups. The local ethics review committee approved the study (Melbourne Health Research and Ethics Committee; reference number 2008.18).

Setting

The research took place at Orygen Youth Health (OYH). OYH is the public youth mental health service for young people aged 15-24 living in the northwestern metropolitan area of Melbourne, Australia. For the purposes of this paper, we will refer to OYH as a tertiary service in that we receive referrals from primary services (e.g. general practitioners) and secondary services (e.g. pediatricians), although we accept any referrals, including direct referrals from young people themselves, their caregivers or places such as education settings. Once accepted by the service, clients are allocated to specialized treatment teams. Focus groups were held with six clinical program teams and with a group of psychiatrists who work across these teams (indicated as MEDICAL in the results section). The clinical programs included the Personal Assessment and Crisis Evaluation (PACE) team for young people considered to be at incipient risk of developing a psychotic disorder, the Early Psychosis Prevention and Intervention Clinic (EPPIC) for young people experiencing a first episode of psychosis, the Youth Mood Clinic (YMC) for moderately and severely depressed young people, the Helping Young People Early (HYPE)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

clinic for emerging borderline personality disorder, the Intensive Mobile Youth Outreach Service (IMYOS) for YMC and HYPE clients who need outreach assistance, and the Youth Access Team (YAT) who provide three main functions: triage by telephone for all referrals; assessment and allocation to the most appropriate clinic; and a 24 hour acute service for OYH clients in crisis. The majority of these clinics have some clinic-specific guidance about management of young people in their clinic; however, with the exception of the YMC, this is not specific to treating depression. The YMC clinic guidance is broadly consistent with guideline recommendations in that they propose cognitive behavioural therapy (CBT) as a first line treatment and selective serotonin reuptake inhibitor (SSRI) fluoxetine as the first line medication. There is no specific guidance within the organization about using externally produced guidelines.

Participants

All clinicians (psychiatrists (approximately 29%), nurses (approximately 14%) and allied health professionals, including psychologists (approximately 32%), occupational therapists (approximately 14%) and social workers (approximately 12%) from OYH who gave informed consent were eligible for inclusion in the study. Therefore, the term ‘clinician’ when used in the results refers to any of these professionals unless specified. Each clinical team consists of a slightly different mix of clinicians with IMYOS, PACE, HYPE, YMC and PACE made up of allied health professionals, while YAT has approximately 50% nurses and 50% allied health professionals and EPPIC has approximately 15% nurses and

85% allied health professionals. Clinicians had between 0.5 and 18 years experience in youth mental health.

Participants were recruited between January and August 2010. The project was presented at staff and clinical review meetings, after which all clinicians were invited to participate. A time for the focus group was arranged with each team separately.

Data collection

Two of the authors (MS and SH) facilitated the focus groups using a semi-structured focus group schedule. The schedule was designed to 'lead' the participants as little as possible, and the dialogue between the facilitator and participants was treated as equally relevant to the data. Participants were given a written copy of the four key recommendations of the NICE guidelines for the treatment of depression in children and adolescents (see Box 1). These recommendations were chosen as exemplars of the recommendations made in similar guidelines internationally and in the absence of published Australian guidelines. Subsequent to this study, Australian guidelines have been published, with recommendations entirely consistent with those presented to the focus groups (CBT/IPT as first line treatment for moderate to severe depression with fluoxetine considered if the psychological treatment is not effective, although no guidance is given about how long psychological therapy should be trialed before fluoxetine is considered; close monitoring is recommended with similar guidance as to the timing). Participants

were asked to comment on barriers (“things that make it difficult to do”) to following these recommendations. The focus groups were audio recorded and transcribed using an orthographic (verbatim) style, and field notes were taken during each focus group by MS or SH. Each focus group was attended by between 8 and 12 clinicians with attendance varying between 75 and 85% of clinicians working on the day of the focus group. Each focus group lasted between 23 and 48 minutes (mean time = 36.4 minutes).

Data analysis

Due to the lack of research in this area, our primary aim was to obtain a descriptive account of the barriers to implementing the key recommendations from the NICE guideline. We used thematic analysis with initial coding undertaken by two authors (SH and MS). The main themes that arose were barriers that exist at 1. the individual clinician level; 2. the clinical level in terms of the presentation of young people; and 3. the systemic or service level. Barriers identified in the data were therefore classified according to these themes in subsequent coding.

Results

Recommendation 1:

“Young people with moderate to severe depression should be offered, as a first-line treatment, a specific psychological therapy (individual cognitive behavioural therapy [CBT], interpersonal therapy or shorter-term family therapy; it is suggested that this should be of at least 3 months’ duration)”

Individual clinician

Across all clinics, except EPPIC (who primarily treat psychosis and stated a preference to see psychosis resolved before diagnosing and treating depression), clinicians expressed a belief that medication was necessary earlier for severe and complex presentations: *“(if they are) severe, I think they should be offered medication first”* (YMC). If therapy could not be initiated, for whatever reasons, there was an implied belief that it would be unethical to withhold medication: *“one often feels more compelled to prescribe because, just because of the long delay. So if a patient was coming into Orygen, it could easily be six to eight week delay before you start any sort of psychological intervention for depression. That's unethical to just hold a patient for that long without an intervention”* (MEDICAL).

Clinical presentation

Clinicians from several clinics stated that the guidelines were not suited to tertiary services, highlighting the lack of evidence specific to the severe and complex presentations of young people who often had comorbid diagnoses, suicide risk, significantly impaired functioning, few supports or social networks, unstable or unsafe accommodation, and extreme financial hardship. Clinicians highlighted that such young people are often too unwell to do therapy *“if ultra severe, then I would suggest there's not much point going into therapy just yet”* (YMC). Clinicians also stated that young people

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

themselves, especially those with severe and complex presentations, were sometimes reluctant to engage in therapy.

Service Level

Clinicians described one barrier related to the wider system of care. The primary issue was that young people were often already on medication *“Australia doesn’t have a tiered system like the UK – some young people come straight to a tertiary service”* (HYPE).

There were also barriers at the local system level in that medication was often commenced at YAT before young people were seen by the specialist clinics. Another barrier was the lack of availability of doctors, with limited access to doctors influencing the timing of medication prescription: *“so if you choose one week not to commence medication but you can’t get an appointment with your doctor to see that client for another month, are you going to be able to hold off on the decision? Probably not.”* (EPPIC). A lack of psychologists both within and outside of the service, and a lack of clinicians trained specifically in CBT or IPT was seen as a barrier by medical staff and clinicians in YAT, EPPIC and IMYOS. Clinicians from all clinics were unclear about what ‘therapy’ meant in the guideline and were concerned that the *“guideline (recommendation) doesn’t acknowledge the importance of case management or engagement”* (YMC).

Large caseloads were an issue, particularly in EPPIC, where case managers might only see a client every two or three weeks. In this situation, six weeks of therapy can take many months to deliver, with some clinicians stating it was 'unreasonable' not to commence medication.

Recommendation 2:

"If moderate to severe depression in a young person is unresponsive to a specific psychological therapy after four to six sessions, fluoxetine should be offered".

Individual clinician

Most clinicians acknowledged fluoxetine should be first-line medication, but clinicians in several clinics (YAT, PACE, EPPIC, MEDICAL) expressed a belief that, depending on the presenting issues of the client, guideline recommendations need not be adhered to *"rather than prescriptively being told to use fluoxetine, we try to manage symptoms. So if they are having problems with sleep, we look for medication that's going to help with that"* (YAT). Medications other than fluoxetine were offered by doctors due to a belief that fluoxetine made anxiety symptoms worse. As for recommendation 1, clinicians expressed a view that medication should be started earlier for severe and complex presentations. On the other hand clinicians in several clinics stated *"four weeks of therapy is not enough to give therapy a go for somebody who has severe [depression]"* (PACE).

Clinical presentation

Engaging young people in medication treatment was at times endorsed as a barrier: *“I’ve got a patient who isn’t keen on medication”* (YMC). Clinicians from the majority of clinics saw patient choice as an important factor in treatment decision-making. Engaging the young person’s family was also stated to be a barrier, with clinicians preferring that the family be involved: *“obviously you need the support of the family”* (YAT). Medical staff highlighted the potential of negative media about antidepressants to influence young people’s and carers’ views about medication.

The relevance of guidelines was again cited as a barrier by several clinics; the (NICE) guidelines were relevant only for those up to the age of 18.

Service Level

Similar system level barriers were highlighted as for recommendation 1 with clinicians stating there was little choice about the timing or type of medication if young people were already on medication. Other barriers included within-clinic procedures that did not include a standard 4 to 6 week review. YMC clinicians, on the other hand, stated *“if anything is not working after four to six weeks, then the treatment should be reviewed and changed”*. Finally, orientation of new registrars to the service was cited as a potential barrier with clinicians stating they noticed more prescriptions of medication other than fluoxetine when new registrars began.

Recommendation 3:

“Antidepressant medication should not be offered to a child or young person with moderate to severe depression except in combination with a concurrent psychological therapy”.

Individual clinician

A belief that it was better for young people to have some treatment (i.e. medication in the context of some case management) than no treatment at all was a barrier described by clinicians in three clinics (YMC, IMYOS & HYPE). One of the medical staff suggested that *“if it is a very early stage, you want to just make sure they are taking medication and getting some response”*, highlighting the concern clinicians have to see treatment responsiveness.

Clinical presentation

Similar to barriers for recommendation 1, difficulty engaging a young person in therapy was seen as a barrier: *“there’s a group with depression as part of intellectual disability or autism who are essentially harder to engage in therapy”* (YMC). These are different examples of the type of complex and severe presentations seen in public mental health services and clinicians consistently highlighted how difficult young people with these types of presentations were to engage in therapy.

Service Level

Clinic based care was stated to be a barrier as young people can find it difficult attend sessions. It was suggested by several clinics that a young person who was only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

interested in medication would probably be linked in with a GP (via a referral either back to the GP who referred the young person or to a GP known to the service to be ‘youth friendly’ and with a particular interest in mental health disorders), although YMC clinicians stated that they would be “*chasing them for a few months*”.

As for recommendation 1, clinicians highlighted the lack of clarity about the term ‘therapy’, stating that they “*do psychological interventions but its not therapy*” (YAT). Many of the clinicians stated that they use ‘psychologically informed case management’ and were uncertain whether this is what is referred to in the guidelines. It is unclear exactly what clinicians are delivering in this case.

Similar to barriers cited for recommendation 1 and 2, some clinics highlighted the lack of psychologists and the fact that young people may have already been prescribed mediation by a GP without the commencement of psychological treatment.

Recommendation 4:

“*Specific arrangements must be made for careful monitoring of adverse drug reactions, as well as for reviewing mental state and general progress; for example, weekly contact with the child or young person and their parent(s) or carer(s) for the first 4 weeks of treatment*”.

Individual clinician

While clinicians across all clinics were confident about their ability to undertake a mental state examination and monitor risk, non-medical clinicians stated they felt “*professionally incompetent*” asking and discussing physical symptoms (PACE) and were unsure about what side effects to monitor (PACE & EPPIC). Clinicians stated they tended to ask general questions about “any side effects” rather than about specific side effects (EPPIC). While non-medical clinicians would not be expected to monitor side effects of medication, it is the case that they are in regular contact with their clients and therefore in a position to be able to screen for and report to the medical staff any side effects noted, in what is a team based approach to care.

In terms of using standardised tools for undertaking monitoring of symptoms and adverse effects, only the YMC clinic had implemented the PH9 (33), a self report depression severity measure, to monitor symptoms (at entry and review); however, clinicians stated that “*pulling out an instrument....could be a bit counter productive and a bit impersonal*”. Clinicians stated they tended to rely on spontaneous report: [we] “*encourage people to get in contact with us by phone, particularly if there’s an emergent suicidal reaction*” (HYPE). Clinicians in several clinics were keen on a system whereby young people were encouraged to be involved in self-monitoring and contact them if they were experiencing side effects, with clinicians in one clinic highlighting the heavy load of mandatory outcome measures as a barrier to using further standardized tools.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Clinical presentation

The majority of clinics stated that severity and complexity of presentation was a barrier to any form of monitoring in young people who were difficult to engage, did not attend and were difficult to contact.

Service Level

Communication between clinicians was stated to be a barrier with, for example, clinicians in the YMC clinic cited delays in the transfer of clients from YAT to a case manager whereby there may be a *“variable amount of time...before they see the OCM....people probably go for a few weeks without anyone checking them”*.

Clinicians in several clinics stated that a lack of availability of clinicians, particularly, medical staff was a barrier to routine monitoring as the young person’s own doctor may not be available or that *“its difficult to fit people within that (guideline recommended) timeframe. There’s just no appointments free”* (HYPE). In terms of other resources, a lack of simple but thorough information on medication and their side effects was stated to be a barrier. This is in the context of existing OYH resources about medication, as well as a range of other information including online resources; that clinicians did not think was entirely appropriate for their use.

Discussion

Principal findings

The results of our study show that the key barrier to implementing guideline recommendations was clinician belief that the guideline recommendations were not relevant to many of the young people who present to a tertiary level mental health service. Clinicians stated that because young people presenting to the service often had severe and complex depression, including high suicide risk, medication was often required earlier than guidelines recommended, that fluoxetine may not be the medication of choice depending on the mix of symptoms, and that it was difficult to deliver psychological therapy. Patient preference was cited as a barrier to delivering guideline recommended care. Furthermore, clinicians agreed that the importance of delivering support and case management to address client's needs was neglected in guideline recommendations.

Service level barriers included a lack of psychologists to deliver psychological interventions, as well as a lack of medical staff to provide regular review and guideline recommended monitoring. Monitoring of side effects was a passive process that relied on spontaneous report from the client, or general enquiry about side effects due to a perceived lack of expertise and a lack of time. In terms of the wider system, young people were often already on medication with little information about their treatment history when they presented to the tertiary service, making sequencing interventions according to guideline recommendations impossible.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and weakness of the study

This study had a high rate of participation and a large sample size, which increases generalisability significantly. However, we did not have 100% participation, and focus group methodology cannot ensure that all possible views are captured. It is interesting that while clinicians included in this study are from different clinics, treating different populations and have different philosophies and staff mix, there was relatively high reported concordance with regard to barriers to implementing guideline recommendations. This is no doubt reflective of common organizational issues and approaches that aim to meet the needs of a population with severe and complex needs.

The findings may not be broadly applicable to services other than public mental health service for youth aged 15 to 25. However, it is likely that other public mental health services such as child and adolescent mental health services, which have a similar mix of professionals and see a similar group of clients in terms of presenting issues albeit of a younger age, may experience similar barriers to implementing guideline recommendations. We did not ask clinicians to specify their profession or years of experience as they made comments and so can not identify this, though have presented data about profession and years of experience in youth mental health over all. No doubt these factors have an impact on their knowledge of and attitudes to guideline recommendations.

Attitudes reported in this study may not be reflective of behaviour, and therefore an audit is currently underway to assess compliance with guideline recommendations. It is interesting to speculate that on the basis of our findings regarding attitudes to guidelines that practice may be broadly in line with guideline recommendations but that significant improvements may be necessary in some areas.

Strengths and weaknesses in relation to other studies, discussing important differences in results

There are few studies that specifically explore barriers to implementing guideline recommendations for the treatment of youth depression. One study conducted in the UK to explore psychiatrists attitudes to evidence based guidelines indicated positive attitudes to guidelines; however, the barriers and enablers to using guideline recommendations were not examined (34). A study in the US surveyed medical directors about their use of practice system tools, showing these were facilitators of evidence based practice; however, again did not explore other factors that influence the uptake of evidence into practice (35). In a study similar to this, child and adolescent mental health professionals in the US participated in focus groups exploring barriers to evidence based practice for youth mental health generally. While only 51% of clinicians participated (N=19), the consistency of findings with the current study is striking, including barriers related to concerns about the applicability of evidence to the population being treated, a desire for greater emphasis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

on the therapeutic relationship and the need for flexibility in implementing recommendations (36).

Implications

There are several potential responses to the current findings. First, services could develop resources for clinicians that clearly communicate the key guideline recommendations, but include considerations for individualising recommendations relevant to the client population and system configuration (37). Evidence shows that guidelines that take into account local circumstances (38, 39) and are simple and easy to use (40) are more likely to be followed. Local services may also invest further effort toward addressing patient preference and related, engagement of young people in evidence-based treatments. Considering patient preference from the outset is one way to encourage adherence to a treatment decision (41). Finally, given the risk of treatment emergent suicidality, and research that indicates that spontaneous report of side effects does not sufficiently identify all those at risk of suicide (42), services should invest in systems that allow regularly collection of standardized information about adverse effects, which may include clients having a role in self- monitoring.

The implications of our findings also point to the need for service reform where the system of care does not easily facilitate a stepped or sequenced model of care as advocated in the guidelines. Most mental health services are configured to treat those with the most severe mental health problems (approximately 3% of population) (43, 44).

1
2
3
4 Additionally, mental health services predominantly remain configured to provide care for
5
6 young people only up to the age of 18. Young people in early adulthood (18-25) find it
7
8 difficult to access appropriate mental health care. There is a need to invest in
9
10 collaborative care models of care that ensure integration between existing primary and
11
12 secondary care and enhanced specialist early intervention mental health services for
13
14 young people across the age spectrum up to the age of 25 (45). This requires greater
15
16 government investment in service reforms that ensure accessible and responsive clinical
17
18 service systems for youth.
19
20
21
22
23
24
25
26

27 *Future research*

28
29 Guidelines are based on evidence from trials that typically exclude participants
30
31 with comorbid conditions and suicide risk (16). There is a clear imperative to develop the
32
33 evidence base to ensure that effective treatments for young people with severe and
34
35 complex disorders that include comorbid conditions, suicide risk and psychosocial
36
37 difficulties, are investigated and disseminated.
38
39
40
41
42
43
44

45 **Acknowledgement**

46
47 Orygen Youth Health receives funds from the Colonial Foundation. Dr Hetrick is
48
49 funded via a NHMRC training fellowship. Ms. Simmons is supported by an Ian Scott
50
51 Scholarship from Australian Rotary Health. The authors would like to thank all the
52
53 clinicians from the service who participated.
54
55
56
57
58
59
60

References

1. Costello JE, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression? *J Child Psychol and Psychiatry* 2006;47(12):1263–71.

2. Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: Prevalence, risk factors and clinical implications. *Clin Psychol Rev* 1998;18(7):765-94.

3. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE, et al. Childhood and adolescent depression: A review of the past 10 years: Part 1. *J Am Acad Child Adolesc Psychiatry* 1996;35(11):1427-39.

4. Beautrais A, Joyce PR, Mulder RT, Fergusson DM, Deavoll BJ, Nightingale SK. Prevalence and comorbidity of mental disorders in persons making serious suicide attempts: a case–control study. *Am J Psychiatry* 1996;153:1009 – 14.

5. Dunn V, Goodyer IM. Longitudinal investigation into childhood- and adolescence-onset depression: psychiatric outcome in early adulthood. *Br J Psychiatry* 2006;188:216-22.

6. Fleischmann A, Bertolote JM, Belfer M, Beautrais A. Completed suicide and psychiatric diagnoses in young people: A critical examination of the evidence. *Am J Orthopsychiatry* 2005;75(4):676-83.

7. Nock MK, Borges G, Bromet EJ, Cha CB, Kessler RC, Lee S. Suicide and suicidal behavior. *Epidemiol Rev* 2008;30:133-54.

8. Rihmer Z, Akiskal H. Do antidepressants treat (en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. *J Affect Disord* 2006;94(1-3):3-13.
9. Laughren TP. *Clinical review: relationship between antidepressant drugs and suicidality in adults*. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Silver Spring, MD: FDA <http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-fda.pdf>; 2006.
10. Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. *Br J Psychiatry* 2006 Nov;189:393-8.
11. Hammad TA, Laughren T, Racoon J. Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry* 2006;63:332-9.
12. Hetrick SE, McKenzie JE, Merry SN. The use of SSRIs in children and adolescents. *Curr Opin Psychiatry* 2010;23:53-7.
13. Goodyer IM, Wilkinson P, Dubicka B, Kelvin R. Forum: The use of selective serotonin reuptake inhibitors in depressed children and adolescents: commentary on the meta-analysis of Hetrick et al. *Curr Opin Psychiatry* 2010;23(58-61).
14. Hebebrand J, March J, Herpertz-Dahlmann B. Commentary on 'Forum: use of antidepressants in children and adolescents'. *Curr Opin Psychiatry* 2010;23(62-67).

15. Dudley M, Hadzi-Pavlovic D, Andrews D, Perich T. New-generation antidepressants, suicide and depressed adolescents: how should clinicians respond to changing evidence. *Aust NZ J Psychiatry*. 2008;42:456-66.

16. Hickie IB, McGorry PD. Guidelines for youth depression: time to incorporate new perspectives. *Med J Aust* 2010;193(3):133-4.

17. Jensen P. After TADS, can we measure up, catch up, and ante up? *Journal of the J Am Acad Child Adoles Psychiatry*. 2006;45(12):1456-60.

18. American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. *J Am Acad Child Adoles Psychiatry* 2007;46(11):1503-26.

19. Cheung AH, Zuckerbrot RA, Jensen PS, Ghalib K, Laraque D, Stein REK, et al. Guidelines for adolescent depression in primary care (GLAD-PC): II treatment and ongoing management. *Pediatrics* 2007;120:e1313-26.

20. National Institute for Health and Clinical Excellence NICE. *Depression in Children and Young People: Identification and management in primary, community and secondary care*. Leicester, UK: The British Psychological Society; 2005.

21. Zuckerbrot RA, Cheung AH, Jensen PS, Stein REK, Laraque D, and the GLAD-PC Steering Group. Guidelines for adolescent depression in primary care (GLAD-PC): I identification, assessment and initial management. *Pediatrics* 2007;120:e1313-26.

22. McDermott B, Baigent M, Chanen A, Fraser L, Graetz B, Hayman N, et al. beyondblue Expert Working Committee (2010) *Clinical practice guidelines: Depression in*

adolescents and young adults. Melbourne: beyondblue: the national depression initiative; 2010.

23. Grol R. Successes and Failures in the Implementation of Evidence-Based Guidelines for Clinical Practice. *Med Care* 2001;39(8(suppl2)):II-46-II-54.

24. Page AN, Swannell S, Martin G, Hollingworth S, Hickie IB, Hall WD. Sociodemographic correlates of antidepressant utilisation in Australia. *Med J Australia* 2009;190:479-83.

25. Morrato EH, Libby AM, Orton HD, deGruy FV, Brent DA, Allen R, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. *Am J Psychiatry* 2008;165:42-50.

26. Perera A, Gupta P, Samuel R, Berg B. A survey of anti-depressant prescribing practice and the provision of psychological therapies in a South London CAMHS from 2003–2006. *Child Adolesc Ment Health* 2007;12(2):70-2.

27. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. *Health Technol Assess* 2004;8(6):iii-iv, 1-72.

28. Baker R, Camosso-Stefinovic J, Gillies C, Shaw EJ, Cheater F, Flottorp S, et al. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev* 2010;Issue 3(CD005470).

29. Grol R. Knowledge transfer in mental health care: how do we bring evidence into everyday practice? *Can J Psychiatry* 2008;53:275-6.

30. Ashton M, Lawn S, Hosking JR. Mental health workers' views on addressing tobacco use. *Aust NZ J Psychiatry* 2010;44:846-51.

31. Gergen KJ. The social constructionist movement in modern psychology. *Am Psychol* 1985;40(266-275).

32. Gergen KJ. *An invitation to social construction*. London: Sage; 2001.

33. Spitzer R KK, Williams J. Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. *J Am Med Assoc* 1999;282:1737-44.

34. Rees H, Sipos A, Spence M, Harrison G. Attitudes of psychiatrists to evidence-based guidelines: a questionnaire survey. *Psychiatr Bull* 2002;26:421-6.

35. Margolis KL, Solberg LI, Asche SE, Whitebird RR. Use of practice system tools by medical groups for depression. *Am J Manag Care* 2007;13(1):305-11.

36. Nelson TD, Steele RG, Mize JA. Practitioner attitudes toward evidence-based practice: themes and challenges. *Adm Policy Ment Health & Ment Health Serv Res* 2006;33:398–409.

37. Gagliardi AR, Brouwers MC, Palda VA, Lemieux-Charles L, Grimshaw JM. How can we improve guideline use? A conceptual framework of implementability. *Implement Sci* 2011;6:26.

38. Davies J, Freemantle N, Grimshaw J, Hurwitz B, Long A, Russell IT. Implementing clinical practice guidelines: Can guidelines be used to improve clinical practice? . *Eff Health Care Bull* 1994;1:1-12.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
39. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. *Can Med Assoc J* 1997;157:408-16.
40. Bauer MS. A review of quantitative studies of adherence to mental health clinical practice guidelines. *Harv Rev Psychiatry* 2002;10:138-53.
41. Simmons M, Hetrick S, Jorm A. Shared decision making: benefits, barriers and current opportunities for application. *Australas Psychiatry* 2010;18(5):394-7.
42. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. *Am J Psychiatry* 2009;166(4):418-26.
43. Andrews G, Toitov N. Changing the face of mental health through needs-based planning. *Aust Health Rev* 2007;31:s122-8.
44. Patel V, Flisher AJ, Hetrick SE, McGorry PD. Mental health of young people: a global public-health challenge. *Lancet* 2007;369(9669):1302-13.
45. Catania LS, Hetrick SE, Newman LK, Purcell R. Prevention and early intervention for mental health problems in 0-25 year olds: are there evidence-based models of care? *Advances in Mental Health*. 2011;in press (accepted 19 July 2011).

Figure 1: Key Recommendations from the NICE guideline

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key Recommendation 1: Young people with moderate to severe depression should be offered, as a first-line treatment, a specific psychological therapy (individual cognitive behavioural therapy [CBT], interpersonal therapy or shorter-term family therapy; it is suggested that this should be of at least 3 months' duration).
Key Recommendation 2: If moderate to severe depression in a young person is unresponsive to a specific psychological therapy after four to six sessions, fluoxetine should be offered.
Key Recommendation 3: Antidepressant medication should not be offered to a child or young person with moderate to severe depression except in combination with a concurrent psychological therapy.
Key Recommendation 4: Specific arrangements must be made for careful monitoring of adverse drug reactions, as well as for reviewing mental state and general progress; for example, weekly contact with the child or young person and their parent(s) or carer(s) for the first 4 weeks of treatment.